Zevra Therapeutics Overview
Zevra Therapeutics Target Price
Analysts' 12-month price predictions for ZVRA.
Get informed when a big investor buys or sells
+ FollowShare Price
$13.98
Average Target Price
$28.20
101.7% upside
101.7% upside5 analysts in the last 4 months
High: $35 | Low: $23
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-06-10 | Maxim GroupJason McCarthy | $35 | 150.4% upside |  |
| 2026-06-10 | GuggenheimEddie Hickman | $29 | 107.4% upside | |
| 2026-06-09 | Canaccord GenuitySumant Kulkarni | $29 | 107.4% upside | |
| 2026-05-08 | GuggenheimEddie Hickman | $25 | 78.8% upside | |
| 2026-03-10 | GuggenheimEddie Hickman | $23 | 64.5% upside | |
| 2025-12-30 | H.C. WainwrightBrandon Folkes | $26 | 86% upside | |
| 2025-11-06 | Cantor FitzgeraldKristen Kluska | $24 | 71.7% upside | |
| 2025-11-06 | Canaccord Genuity | $24 | 71.7% upside | |
| 2025-03-13 | Guggenheim | $22 | 57.4% upside | |
| 2025-03-12 | JMP Securities | $18 | 28.8% upside | |
| 2025-02-04 | GuggenheimZevra Therapeutics to $ | $21 | 50.2% upside | |
| 2024-09-24 | Roth CapitalJonathan Aschoff | $21 | 50.2% upside | |
| 2024-09-24 | Maxim GroupJason McCarthy | $25 | 78.8% upside | |
| 2024-09-24 | JMP SecuritiesJason Butler | $17 | 21.6% upside | |
| 2024-09-23 | H.C. WainwrightOren Livnat | $20 | 43.1% upside | |
| 2024-09-18 | Canaccord GenuitySumant Kulkarni | $22 | 57.4% upside | |